Neutralizing TNF-alpha activity modulates T-cell phenotype and function in experimental autoimmune uveoretinitis

Journal of Autoimmunity

Volumn 11, Issue 3, 1998, Pages 255-264

  Dick, Andrew D ^a   Duncan, Linda ^b   Hale, Geoff ^b   Waldmann, Herman ^b   Isaacs, John ^b  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b NONE

Author keywords

Apoptosis; Cytokines; Experimental autoimmune uveoretinitis (EAU); Th2 T cells; Tumour necrosis factor alpha

Indexed keywords

CYTOKINE; TUMOR NECROSIS FACTOR ALPHA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; AUTOIMMUNITY; CELL ISOLATION; CELL PROLIFERATION; FLOW CYTOMETRY; GENE TARGETING; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RAT; RETINA CELL; T LYMPHOCYTE ACTIVATION; TISSUE INJURY; UVEORETINITIS; VASCULAR ENDOTHELIUM;

EID: 0031820107     PISSN: 08968411     EISSN: None     Source Type: Journal    
DOI: 10.1006/jaut.1998.0197     Document Type: Article

References (51)

1. Vassalli P. 1992. The apthophysiology of tumour necrosis factors. Annual Review of Immunology 10: 411-452
2. Ruddle N.H., Bergman C.M., McGrath K.M., Lingenheld E.G., Grunnet M.L., Padula S.J., Clark R.B. 1990. An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. J. Exp. Med. 172: 1193-1200
3. Selmaj K., Raine C.S., Cross A.H. 1991. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann. Neurol. 30: 694-700
4. Williams R.O., Ghrayeb J., Feldmann M., Maini R.N. 1995. Successful therapy of collagen-induced arthritis with TNF receptor-IgG fusion protein and combination with anti-CD4. Immunology 84: 433-439
5. Yang X.D., Tisch R., Singer S.M., Cao Z.A., Liblau R.S., Schreiber R.D., McDevitt H.O. 1994. Effect of tumor necrosis factor alpha on insulin-dependent diabetes mellitus in NOD mice. I. The early development of autoimmunity and the diabetogenic process. J. Exp. Med. 180: 995-1004
6. Elliott M.J., Maini R.N., Feldmann M., Kalden J.R., Antoni C., Smolen J.S., Leeb B., Breedveld F.C., Macfarlane J.D., Bijl H., Woody J.N. 1994. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. The Lancet 344: 1105-1110
7. Elliott M.J., Maini R.N., Feldmann M., Long-Fox A., Charles P., Katsikis P., Brennan R.M., Walker J., Bijl H., Ghrayeb J., Woody J.N. 1993. Treatment of Rheumatoid Arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum. 36: 1681-1690
8. Moreland L.W., Baumgartner S.W., Schiff M.H., Tindall E.A., Flaeischmann R.M., Weaver A.L., Ettlinger R.E., Cohen S., Koopman W.J., Mohler K., Widmer M.B., Blosch C.M. 1997. Treatment of rheumatoid arthritis with recombinant human tumour necrosis factor receptor (p7S)-Fc fusion protein. New. Engl. J. Med. 337: 141-147
9. Selmaj K., Raime C.S., Farooq M., Norton W.T., Brosnan C.F. 1991. Cytokine cytotoxicity against oligodendrocytes. Apoptosis induced by lymphotoxin. J. Immunol. 147: 1522-1529
10. Zheng L., Fisher G., Miller R.E., Peschon J., Lynch D.H., Lenardo M.J. 1995. Induction of apoptosis in mature T cells by tumour necrosis factor. Nature 377: 348-351
11. Pender M.P., Nguyen K.B., McCombe P.A., Kerr J.F.R. 1991. Apoptosis in the nervous system in experimental allergic encephalomyelitis. J. Neurol. Sci. 104: 81-87
12. Hickey W.F., Kimura H. 1988. Perivascular microglial cells of the CNS are bone marrow derived and present antigen in vivo. Science 239: 290-292
13. Isaacs J.D. 1997. Immunotherapies for immunomodulation of autoimmune and rheumatic disease. Brit. J. Rheumatol. 36: 305-309
14. Scallon B.J., Moore M.A., Trinh H., Knight D.M., Ghrayeb J. 1995. Chimeric anti-TNF-α monoclonal antibody cA2 binds soluble recombinant transmembrane TNFa and activates immune effector functions. Cytokine 7: 251-259
15. Körner H., Goodsall A.L., Lemckert F.A., Scallon B.J., Ghrayeb J., Ford A.L., Sedgwick J.D. 1995. Unimpaired autoreactive T cell traffic within the CNS during tumor necrosis factor-receptor-mediated inhibition of experimental autoimmune encephalomyelitis. Proc. Natl. Acad. Sci. USA 92: 11066-11070
16. Dick A.D., McMenamin P.G., Korner H., Scallon B.J., Ghrayeb J., Forrester J.V., Sedgwick J.D. 1996. Inhibition of tumour necrosis factor activity minimizes target organ damage in experimental autoimmune uveoretinitis despite quantitatively normal activated T cell traffic to the retina. Eur. J. Immunol. 26: 1018-1025
17. Baker D., Butler D., Scallon B.J., O'Neill J.K., Turk J.L., Feldmann M. 1994. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24: 2040-2048
18. Forrester J.V., Liversidge J., Dua H.S., Towler H., McMenamin RG. 1990. Comparison of clinical and experimental uveitis. Curr. Eye Res. 9: 75-81
19. Caspi R.R., Roberge F.G., McAllister C.G., el Saied M., Kuwabara T., Gery I., Hanna E., Nussenblatt R.B. 1986. T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol. 136: 928-933
20. Dick A.D. 1995. Experimental approaches to specific immunotherapies in autoimmune disease: future treatment of endogenous posterior uveitis. Brit. J. Ophthalmol. 79: 81-89
21. Sartani G., Silver P.B., Rizzo L.V., Chan C.C., Wiggert B., Mastorakos G., Caspi R.R. 1996. Anti-tumour necrosis factor alpha therapy suppresses the induction of experimental autoimmune uveoretinitis in mice by inhibiting antigen priming. Invest. Ophth. Vis. Sci. 37: 2211-2218
22. Dick A.D., Cheng Y.F., Liversidge J., Forrester J.V. 1994. Immunomodulation of experimental autoimmune uveoretinitis: a model of tolerance induction with retinal antigens. Eye 8: 52-59
23. Laliotou B., Liversidge J., Forrester J.V., Dick A.D. 1997. Interphotoreceptor retinoid binding protein is a potent tolerogen in Lewis rat: suppression of experimental autoimmune uveoretinitis is retinal antigen specific. Brit. J. Ophthalmol. 81: 1-7
24. low parenchyma microglia. Brit. J. Ophthalmol. 79: 834-840
25. Sedgwick J.D., Schwender S., Imrich H., Dörries R., Butcher G.W., ter Meulen V. 1991. Isolation and direct characterization of resident microglial cells from the normal and inflamed central nervous system. Proc. Natl. Acad. Sci. USA. 88: 7438-7442
26. Vermes I., Haansen H., Steffens-Nakken H., Reutelingsperger C. 1995. A novel assay for apoptosis. Flow cytometric detection of phosphatidylerine expression on early apoptotic cells using fluorescein labelled Annexin V. J. Immunol. Methods 184: 39-51
27. McMenamin C., Holt RG. 1993. The natural immune response to inhaled soluble protein antigens involves major histocompatability complex (MHC) class I-restricted CD8+ T cell mediated but MHC class II-restricted CD4+ T cell-dependent immune deviation resulting in selective suppression of immunoglobulin E production. J. Exp. Med. 178: 889-899
28. Powrie F.D.M. 1990. Ox22high CD4+ T cells induce wasting disease with multiple organ pathology: prevention of the Ox-221ow subset. J. Exp. Med. 172: 1701-1708
29. Fowell D., Mason D. 1993. Evidence that the T cell repertoire of normal rats contains cells with the potential to cause diabetes. Characterization of the CD4+ T cell subset that inhibits this autoimmune potential.. J. Exp. Med. 177: 627-636
30. Springer T.A. 1994. Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76: 301-314
31. Feldmann M., Brennan F., Maini R.N. 1996. Role of cytokines in rheumatoid arthritis. Annu. Rev. Immunol. 14: 397-440
32. Frei K., Eugster H.P., Bopst M., Constantonescu C.S., Lavi E., Fontana A. 1997. Tumour necrosis factor alpha and lymphotoxin alpha are not required for induction of acute experimental autoimmune encephalomyelitis. J. Exp. Med. 185: 2117-2182
33. Cope A.P., Liblau R.S., Yang X.D., Congia M., Laudanna C., Schreiber R.D., Probert L., Kollias G., McDevitt H.O. 1997. Chronic tumour necrosis factor alters T cell responses by attenuating T cell receptor signaling. J. Exp. Med. 185: 1573-1584
34. deKozak Y., Cotinet A., Goureau O., Hicks D., Thillaye-Goldenberg B. 1997. Tumour necrosis factor and nitric oxide production by resident glial cells from rats presenting hereditary retinal degeneration. Ocular Immunol. Inflamm. 5: 85-94
35. Renno T., Krakowski M., Piccirillo C., Lin J., Owens T. 1995. TNF-alpha expression by resident microglia and infiltrating leukocytes in the CNS of mice with experimental allergic encephalomyelitis: regulation of Th1 cytokines. J. Immunol. 154: 944-953
36. Barton K., Calder V.L., Lightman S. 1993. Isolation of retinal lymphocytes in experimental autoimmune uveoretinitis: phenotypic and functional characterization. Immunology 78: 393-398
37. Mosmann T.R., Coffman R.L. 1989. Th1 and Th2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7: 145-153
38. Ramanathan S., de Kozak Y., Saoudi A., Goureau O., Van der Meide P.H., Druet P., Bellon B. 1996. Recombinant IL-4 aggravates experimental autoimmune uveoretinitis in rats. J. Immunol. 157: 2209-2215
39. Caspi R.R., Chan C.C., Grubbs B.G., Silver P.B., Wiggert B., Parsa C.F., Bahmanyar S., Billiau A., Heremans H. 1994. Endogenous systemic IFN-gamma has a protective role against ocular autoimmunity in mice. J. Immunol. 152: 890-899
40. Jones L.S., Rizzo L.V., Agarwal R.K., Tarrant T.K., Chan C.C., Wiggert B., Caspi R.R 1997. IFN-gamma-deficient mice develop experimental autoimmune uveitis in the context of a deviant effector response. J. Immunol. 158: 5997-6005
41. Charteris D.G., Lightman S.L. 1992. Interferon-gamma production in vivo in experimental autoimmune uveoretinitis. Immunology 75: 463-467
42. Cash E., Minty A., Ferrara P., Caput D., Fradelizi D., Rott O. 1994. Macrophage-inactivating IL-13 suppresses experimental autoimmune encephalomyelitis in rats. J. Immunol. 153: 4258-4267
43. Groux H., O'Garra A., Bigler M., Rouleau M., Antonenko S., deVries J.E., Roncarolo M.G. 1997. A CD4+ T cell subset inhibits antigen-specific T cell responses and prevents colitis. Nature 389: 737-741
44. Yokoi H., Kato K., Kezuka T., Sakai J., Usui M., Yagita H., Okumura K. 1997. Prevention of experimental autoimmune uveoretinitis by monoclonal antibody to interleukin-12. Eur. J. Immunol. 27: 641-646
45. Healey D., Ozegbe P., Arden S., Chandler P., Hutton J., Cooke A. 1995. In vivo activity and in vitro specificity of CD4+ Th1 and Th2 cells derived from the spleens of diabetic NOD mice. J. Clin. Invest. 95: 2979-2985
46. Ford A.L., Foulcher E., Lemckert E., Sedgwick J.D. 1996. Microglia induce CD4 T-lymphocyte final effector function and death. J. Exp. Med. 184: 1737-1745
47. Munn D., Pressey J., Beall A.C., Hudes R., Alderson M.R. 1996. Selective activation-induced apoptosis of peripheral T cells imposed by macrophages. J. Immunol. 156: 523-532
48. Liversidge J., Sewell H.F., Forrester J.V. 1990. Interactions between lymphocytes and cells of the blood retinal barrier: mechanisms of T-lymphocyte adhesions to human retinal capillary endothelial cells and retinal pigment epithelial cells in vitro. Immunology 71: 390-396
49. Roberge F.G., Caspi R.R., Nussenblatt R.B. 1988. Retinal Muller cells produce IL-1 activity and have a dual effect on autoimmune T-helper cells. J. Immunol. 140: 2193-2199
50. de Kozak Y., Naud N.C., Bellot J., Faure J.P., Hicks D. 1994. Differential tumor necrosis factor expression by resident retinal cells from experimental uveitis-susceptible and -resistant rat strains. J. Neuroimmunol. 55: 1-9
51. Selmaj K., Papierz W., Glabinski A., Kohno T. 1995. Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J. Neuroimmunol 56: 135-141